MicroPharm is pleased to announce that is has recently been granted an Animal Trial Certificate by the Veterinary Medicines Directorate to perform clinical trials on its new veterinary antivenom, ViperaVet, developed for the treatment of dogs envenomed by one of the four medically important species of Vipera (adder) found throughout Western Europe.  In the UK, the Veterinary Poisons Information Service receives 100 – 150 enquiries regarding treatment of adder bites but we estimate that the true incidence is at least 8 to 10 times this figure.  Although mortality is relatively low in dogs, bites may result in severe clinical signs requiring intensive treatment and hospitalisation.  At present, there is no licenced veterinary antivenom for use in Europe, so a product for human use has been used to date.  However, this has become extremely difficult to procure for veterinary use, creating a niche market for a veterinary product.

ViperaVet contains purified ovine antibody fragments directed against the venoms of four Vipera species which are found throughout Europe.  These antibodies bind to and neutralise the major venom components of these species of snake, shown in both in vitro and in vivo assays, showing antivenom efficacy.  Early results from the clinical trial in the UK indicate that the product is both safe and effective.  We look forward to extending the clinical trial both in the UK and other European countries.